Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2341 to 2355 of 7679 results

  1. Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over ID 6475

    Awaiting development [GID-TA11586] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]

    In development [GID-TA10571] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  3. Fetoscopic tracheal occlusion (FETO) for severe congenital diaphragmatic hernia

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  4. Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer ID6399

    Awaiting development [GID-TA11499] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]

    Awaiting development [GID-TA11299] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]

    In development [GID-TA10904] Expected publication date: 15 January 2025

    Technology appraisal guidance
    In development

  7. Guselkumab for previously treated moderately to severely active Crohn's disease ID6238

    In development [GID-TA11245] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Guselkumab for treating moderately to severely active ulcerative colitis ID6237

    In development [GID-TA11247] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339

    In development [GID-TA11432] Expected publication date: 02 July 2025

    Technology appraisal guidance
    In development

  10. Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

    In development [GID-TA10990] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  11. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]

    In development [GID-TA11197] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pembrolizumab for neoadjuvant and with radiotherapy for adjuvant treatment of newly diagnosed resectable locally advanced squamous cell head and neck cancer TS ID 12068

    Awaiting development [GID-TA11599] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

    In development [GID-TA11373] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Artificial intelligence software to help detect and characterise colorectal polyps

    In development [GID-DG10118] Expected publication date: TBC

    Diagnostics guidance
    In development